Certolizumab Pegol is Effective for Chronic Plaque Psoriasis Across Patient Subgroups: A Pooled Subanalysis from Ongoing Phase 3 Studies (CIMPASI-1, CIMPASI-2, and CIMPACT)
Author Type(s)
Faculty
Document Type
Abstract
Publication Date
9-2018
Journal Title
Journal of the American Academy of Dermatology
Department
Dermatology
Recommended Citation
Reich, K., Gottlieb, A. B., Blauvelt, A., Sofen, H., Weglowska, J., Augustin, M., Poulin, Y., Burge, J. D., Peterson, L., Rolleri, R., & Leonardi, C. (2018). Certolizumab Pegol is Effective for Chronic Plaque Psoriasis Across Patient Subgroups: A Pooled Subanalysis from Ongoing Phase 3 Studies (CIMPASI-1, CIMPASI-2, and CIMPACT). Journal of the American Academy of Dermatology, 79 (3 Suppl.1), AB66. Retrieved from https://touroscholar.touro.edu/nymc_fac_abstracts/347
COinS
